---
title: "ML18147"
slug: "ml"
date: "2023-09-21"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[Metastatic Colon Cancer]]

# ML18147

- [Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial - ScienceDirect](https://www-sciencedirect-com.autorpa.kfsyscc.org/science/article/abs/pii/S1470204512704771?via%3Dihub)

1. Design:

- Phase 3 trial
- Multi-center
- Randomized
- Open-label

2. Number of patients: 820 patients

- 409 patients in the bevacizumab plus chemotherapy group
- 411 patients in the chemotherapy alone group

3. Patients characteristics:

- Patients aged â‰¥18 years with unresectable, histologically confirmed metastatic colorectal cancer progressing up to 3 months after discontinuing first-line bevacizumab plus chemotherapy

4. Agent:

- Bevacizumab plus standard second-line chemotherapy

5. Treatment line:

- Second-line chemotherapy with or without bevacizumab

6. Trial Name or NCT Number: NCT00700102
7. Comparison of two groups:

| Outcome | Bevacizumab plus chemotherapy group | Chemotherapy alone group |
| --- | --- | --- |
| Median overall survival (months) | 11.2 (95% CI 10.4-12.2) | 9.8 (95% CI 8.9-10.7) |
| Hazard ratio | 0.81 | 95% CI 0.69-0.94 |
| Unstratified log-rank test p-value | 0.0062 | not reported |
| Grade 3-5 bleeding or haemorrhage | 8 (2%) | 1 (<1%) |
| Gastrointestinal perforation | 7 (2%) | 3 (<1%) |
| Venous thromboembolisms | 19 (5%) | 12 (3%) |
| Neutropenia | 65 (16%) | 52 (13%) |
| Diarrhoea | 40 (10%) | 34 (8%) |
| Asthenia | 23 (6%) | 17 (4%) |
| Treatment-related deaths | 4 | 3 |
